Visceral adiposity and metabolic dysfunction—insulin resistance, dyslipidemia, adipokine imbalance, and low-grade inflammation—establish a bidirectional liver–kidney crosstalk in MASLD. Here, INS is linked to metabolic dysfunction-associated steatotic liver disease.